{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:09:56Z","timestamp":1781561396118,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Public Incorporated Foundation Tsuchiya Bunka Shinkou Zaidan, Japan."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many molecular targeted agents, including biologics, have emerged for inflammatory bowel diseases (IBD), but their high prices have prevented their widespread use. This study aimed to reveal the changes in patient characteristics and the therapeutic strategies of IBD before and after the implementation of biologics in Japan, where the unique health insurance system allows patients with IBD and physicians to select drugs with minimum patient expenses. The analysis was performed using a prospective cohort, including IBD expert and nonexpert hospitals in Japan. In this study,\u00a0patients were classified into two groups according to the year of diagnosis based on infliximab implementation as the prebiologic and biologic era groups. The characteristics of therapeutic strategies in both groups were evaluated using association analysis. This study analyzed 542 ulcerative colitis (UC) and 186 Crohn\u2019s disease (CD). The biologic era included 53.3% of patients with UC and 76.2% with CD, respectively. The age of UC (33.9\u00a0years vs. 38.8\u00a0years, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) or CD diagnosis (24.3\u00a0years vs. 31.9\u00a0years, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) was significantly higher in the biologic era group. The association analysis of patients with multiple drug usage histories revealed that patients in the prebiologic era group selected anti-tumor necrosis factor (TNF)-\u03b1 agents, whereas those in the biologic era group preferred biologic agents with different mechanisms other than anti-TNF-\u03b1. In conclusion, this study demonstrated that\u00a0both patient characteristics and treatment preferences in IBD have changed before and after biologic implementation.<\/jats:p>","DOI":"10.1038\/s41598-023-40624-5","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T10:02:31Z","timestamp":1692612151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000"],"prefix":"10.1038","volume":"13","author":[{"given":"Takashi","family":"Taida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadahisa","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyo","family":"Mamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Horio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Kurosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shiratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Akizue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotaro","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Koma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosaku","family":"Azemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Kamezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Masuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kitsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Tsuyuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"40624_CR1","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham, C. & Cho, J. H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066\u20132078 (2009).","journal-title":"N. Engl. J. Med."},{"key":"40624_CR2","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/j.1440-1746.2012.07150.x","volume":"27","author":"L Prideaux","year":"2012","unstructured":"Prideaux, L., Kamm, M. A., De Cruz, P. P., Chan, F. K. & Ng, S. C. Inflammatory bowel disease in Asia: A systematic review. J. Gastroenterol. Hepatol. 27, 1266\u20131280 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"40624_CR3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41575-020-0352-2","volume":"17","author":"M Argollo","year":"2020","unstructured":"Argollo, M., Kotze, P. G., Kakkadasam, P. & D\u2019Haens, G. Optimizing biologic therapy in IBD: How essential is therapeutic drug monitoring?. Nat. Rev. Gastroenterol. Hepatol. 17, 702\u2013710 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"40624_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0140-6736(93)91375-V","volume":"342","author":"B Derkx","year":"1993","unstructured":"Derkx, B. et al. Tumour-necrosis-factor antibody treatment in Crohn\u2019s disease. Lancet 342, 173\u2013174 (1993).","journal-title":"Lancet"},{"key":"40624_CR5","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N. Engl. J. Med. 375, 1946\u20131960 (2016).","journal-title":"N. Engl. J. Med."},{"key":"40624_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699\u2013710 (2013).","journal-title":"N. Engl. J. Med."},{"key":"40624_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723\u20131736 (2017).","journal-title":"N. Engl. J. Med."},{"key":"40624_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/ibd\/izx098","volume":"24","author":"E Louis","year":"2018","unstructured":"Louis, E. Stopping biologics in IBD\u2014What is the evidence?. Inflamm. Bowel Dis. 24, 725\u2013731 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"40624_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase, H. et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J. Gastroenterol. 56, 489\u2013526 (2021).","journal-title":"J. Gastroenterol."},{"key":"40624_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres, J. et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: Medical treatment. J. Crohns Colitis 14, 4\u201322 (2020).","journal-title":"J. Crohns Colitis"},{"key":"40624_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord, M. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J. Crohns Colitis 11, 769\u2013784 (2017).","journal-title":"J. Crohns Colitis"},{"key":"40624_CR12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein, J. D. et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 158, 1450\u20131461 (2020).","journal-title":"Gastroenterology"},{"key":"40624_CR13","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein, J. D. et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology 160, 2496\u20132508 (2021).","journal-title":"Gastroenterology"},{"key":"40624_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/CEOR.S293698","volume":"13","author":"T Matsumoto","year":"2021","unstructured":"Matsumoto, T. et al. Changes in the penetration rate of biosimilar infliximab within Japan using a Japanese claims database. Clinicoecon. Outcomes Res. 13, 145\u2013153 (2021).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"40624_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2176\/nmc.st.2016-0135","volume":"57","author":"Y Kanatani","year":"2017","unstructured":"Kanatani, Y. et al. National Registry of Designated Intractable Diseases in Japan: Present status and future prospects. Neurol. Med. Chir. 57, 1\u20137 (2017).","journal-title":"Neurol. Med. Chir."},{"key":"40624_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41575-019-0102-5","volume":"16","author":"P Olivera","year":"2019","unstructured":"Olivera, P., Danese, S., Jay, N., Natoli, G. & Peyrin-Biroulet, L. Big data in IBD: A look into the future. Nat. Rev. Gastroenterol. Hepatol. 16, 312\u2013321 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"40624_CR17","doi-asserted-by":"publisher","DOI":"10.1159\/000529816","author":"Y Ohta","year":"2023","unstructured":"Ohta, Y. et al. Clinical features focusing on extraintestinal manifestations in japanese patients with inflammatory bowel diseases: Far East 1000. Digestion https:\/\/doi.org\/10.1159\/000529816 (2023).","journal-title":"Digestion"},{"key":"40624_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.mayocp.2018.02.012","volume":"93","author":"DT Zemedikun","year":"2018","unstructured":"Zemedikun, D. T., Gray, L. J., Khunti, K., Davies, M. J. & Dhalwani, N. N. Patterns of multimorbidity in middle-aged and older adults: an analysis of the UK Biobank data. Mayo Clin. Proc. 93, 857\u2013866 (2018).","journal-title":"Mayo Clin. Proc."},{"key":"40624_CR19","doi-asserted-by":"publisher","first-page":"1900476","DOI":"10.1183\/13993003.00476-2019","volume":"54","author":"MT Krishna","year":"2019","unstructured":"Krishna, M. T. et al. Allergic diseases and long-term risk of autoimmune disorders: Longitudinal cohort study and cluster analysis. Eur. Respir. J. 54, 1900476 (2019).","journal-title":"Eur. Respir. J."},{"key":"40624_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan, G. G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720\u2013727 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"40624_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","volume":"116","author":"G D\u2019haens","year":"1999","unstructured":"D\u2019haens, G. et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: A European multicenter trial. Gastroenterology 116, 1029\u20131034 (1999).","journal-title":"Gastroenterology"},{"key":"40624_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","volume":"14","author":"M Neurath","year":"2017","unstructured":"Neurath, M. Current and emerging therapeutic targets for IBD. Nat. Rev. Gastroenterol. Hepatol. 14, 269\u2013278 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"40624_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park, K. T. et al. The cost of inflammatory bowel disease: An initiative from the Crohn\u2019s and colitis foundation. Inflamm. Bowel Dis. 26, 1\u201310 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"40624_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jgh.14872","volume":"35","author":"WY Mak","year":"2020","unstructured":"Mak, W. Y., Zhao, M., Ng, S. C. & Burisch, J. The epidemiology of inflammatory bowel disease: East meets west. J. Gastroenterol. Hepatol. 35, 380\u2013389 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"40624_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel, J. F. et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut 66, 839\u2013851 (2017).","journal-title":"Gut"},{"key":"40624_CR26","first-page":"3","volume":"17","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn, W. J., Feagan, B. G., Hanauer, S. B. & Lichtenstein, G. R. The guide to guidelines in ulcerative colitis: Interpretation and appropriate use in clinical practice. Gastroenterol. Hepatol. 17, 3\u201313 (2021).","journal-title":"Gastroenterol. Hepatol."},{"key":"40624_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","volume":"148","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood, G. S. et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: A network meta-analysis. Gastroenterology 148, 344\u2013354 (2015).","journal-title":"Gastroenterology"},{"key":"40624_CR28","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands, B. E. et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 399, 2200\u20132211 (2022).","journal-title":"Lancet"},{"key":"40624_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh, S. et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: A systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 6, 1002\u20131014 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40624-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40624-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40624-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T19:18:37Z","timestamp":1700507917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40624-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40624"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-40624-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sadahisa Ogasawara received honoraria from Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Abbvie G.K.; consulting or advisory fees from Eisai Co., Ltd., and research grants from Eisai Co., Ltd..  Naoya Kato received honoraria from AbbVie G.K., Ohtsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Olympus Corporation, Eisai Co., Ltd., Tsumura & Co., Mochida Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Olympus Marketing, Inc., and Janssen Pharmaceutical K.K., and research funding from Ohtsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd., Tsumura & Co., Nippon Kayaku Co., Ltd., and JIMRO Co., Ltd.  The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13555"}}